Glutaric aciduria type 1 and neonatal screening: time to proceed--with caution. by Superti-Furga, A.
ARTICLE
Andrea Superti-Furga
Glutaric aciduria type 1 and neonatal screening:
time to proceed—with caution
Published online: 25 October 2003
 Springer-Verlag 2003
Abstract The new technology of tandem mass spec-
trometry is having a signiﬁcant impact on the diagnos-
tics of inborn metabolic errors. One of the most
important aspects of this new technology is the possi-
bility of recognising a whole class of disorders within a
single analytical step. Shall this powerful technology be
applied to the screening of newborn babies? Careful
evaluation of every single disorder that could potentially
be identiﬁed is needed. In the following, I will present
some considerations that concern glutaric aciduria type
1 (MIM 231670; glutaryl-CoA dehydrogenase deﬁ-
ciency).
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The natural course of glutaric aciduria type 1
The clinical manifestations of glutaric aciduria type 1
(GA1) have been reviewed by several authors [2, 3, 6, 9,
11, 28]. Essentially, the majority of individuals homo-
zygous for pathogenic mutations in the glutaryl-CoA
dehydrogenase (GADH) gene will develop neurological
disease, either acutely following an encephalopathic
crisis, or, less frequently, with an insidious course. The
neurological disease in GA1 consists of an extrapyra-
midal movement disorder of varying degree; most indi-
viduals who have had an encephalopathic crisis have
severe dystonia with marked disability. Intelligence
usually remains intact. Some individuals are known to
have no neurological disease in spite of proven enzyme
deﬁciency and/or GADH mutations; they are, however,
the exception rather than the rule.
What is the pathogenesis of brain injury
in glutaric aciduria type 1?
It appears that two distinct pathogenetic moments
should be distinguished [28]. Frontotemporal atrophy of
variable degree, often with arachnoid cysts, develops
before birth and probably during some months after
birth [1, 5, 7, 13, 20, 21, 22, 26, 31, 34]. The pathogenetic
mechanism is not understood. Interestingly, there is no
close correlation between the degree of frontotemporal
atrophy in an infant and subsequent neurological
impairment; often there is frank discordance. Subdural
haematoma is a common complication and may lead to
suspected child abuse.
Degeneration of basal ganglia, in particular of the
corpus striatum, is clinically more relevant. As dis-
cussed, this can occur in an insidious way or acutely
following an encephalopathic crisis. Clinical circum-
stantial evidence has pointed to a concurrence of several
factors in the pathogenesis of basal ganglia degeneration
[28]: carnitine depletion, excitotoxic mechanisms, and,
during an acute crisis, hyperthermia with increased en-
ergy requirements and infection with cytokine release.
Moreover, a developmental proﬁle of one or more
neuronal receptor(s) has been advocated to explain the
susceptibility window to acute crises (beyond the age of
4 years or so, acute crises become rare and there is a
tendency to stabilisation of the neurological ﬁndings –
again, with exceptions). Experiments with neuronal cell
cultures have conﬁrmed that metabolites accumulating
in GA1 may elicit excitotoxic and apoptotic pathways
[14, 15, 17, 18, 32] but concentrations used in the studies
have been higher than those observed in body ﬂuids and
these studies fail to explain the lack of correlation be-
tween the concentration of glutaric acid metabolites in
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body ﬂuids and the severity of neurological disease.
Although promising, the studies in cell culture have not
yet thrown conclusive light on the exact mechanisms
triggering neuronal degeneration nor provided avenues
to pharmacological prevention.
Can we prevent the natural course of the disease?
Yes, we can. There is abundant, although indirect, evi-
dence indicating that once the diagnosis of GA1 has
been made, the risk for acute encephalopathy and basal
ganglia degeneration is signiﬁcantly reduced [2, 10, 12,
23]. Unfortunately, no case-control or prospective study
is available, and these conclusions, although accepted by
most experts, are based solely on the retrospective case
collection study of Georg Hoﬀman and coworkers as
well as on observations on single families. Opinions
diﬀer as to what component of our therapeutic arsenal is
more eﬀective. Replenishment of carnitine stores, usu-
ally depleted by the time of diagnosis, may be the single
most eﬀective factor. Avoidance of prolonged hyper-
thermia and catabolism with anti-inﬂammatory medi-
cation, hydration, and caloric supply also plays a role.
Current dietary management includes restriction of
protein intake but not to a degree requiring supple-
mentation with amino acid mixture. No concrete study
has ever shown the eﬃcacy of such an approach; and the
risk of amino acid imbalance is present [25]. The use of
neuroprotective drugs during episodes of fever and
catabolism makes sense and has been advocated, but no
rigorous studies have been conducted and in vitro evi-
dence is equally lacking. Contrary to early reports,
riboﬂavin has not proven to be helpful [4].
Does early diagnosis matter?
Making the diagnosis of GA1 matters at any time in
life. Even in individuals with advanced basal ganglia
injury, carnitine repletion makes them less vulnerable
to further damage and to hypoglycaemic episodes.
Early diagnosis, following the diagnosis in older
aﬀected sibs or because of macrocephaly or arachnoid
cysts, can result in at least partial prevention of sub-
sequent neurological deterioration. Early diagnosis
allows, of course, for adequate genetic counselling
before the onset of further pregnancies.
What have we learnt from current screening
programmes?
Neonatal screening programmes for GA1 have been
going on for several years in selected regions of the
United States and Canada [8, 24], and for 2 to 4 years in
large provinces in Germany (A. Muntau, G. Hoﬀmann,
and A. Roscher, personal communications; and discus-
sion on Metab-L). Without reviewing the details, the
following issues are addressed: (1) the incidence of GA1
in the general population of Europe and North America
appears to be lower than the 1:40,000 extrapolated from
preliminary studies approximately 10 years ago (this
does not apply to selected geographic areas with known
higher incidence of GA1); (2) the timing of blood
sampling may play a role (samples taken too early may
give false negative results); (3) determining the correct
threshold for glutarylcarnitine in the dried blood sam-
ples appears to be problematic; several GA1 cases have
been missed in screening programmes, but lowering the
threshold for glutarylcarnitine would lead to unaccept-
ably high recall rates; (4) neonatal diagnosis followed by
treatment with carnitine, dietary advice, and emergency
management does not necessarily prevent the onset of
neurological disease; some children have developed
encephalopathic crises with neurological damage in spite
of early diagnosis and treatment [8, 16].
Should glutaric aciduria type 1 be included in neonatal
mass screening programmes?
The criteria of Wilson and Jungner [33], long consid-
ered the golden rule for the inclusion in mass screen-
ing programmes, are clearly not fulﬁlled by GA1 [29,
33]. In particular, although the morbidity of the dis-
ease is suﬃciently high to justify screening, the inci-
dence of the disorder remains unknown and treatment
may not prevent disease manifestations in all cases,
thereby raising thorny questions on the ethical
acceptability. Finally, the more frequently used
screening method (tandem mass spectrometry (TMS)
of acylcarnitines in dried blood spots) might not detect
100% of cases. It is clear that both the medical as-
pects of GA1 treatment and the technical issues
(timing of the blood sampling, reﬁning of cutoﬀ
criteria on TMS analysis) need our full attention.
On the other hand, we should not remain captive to
preset criteria. There are several excellent reasons to
proceed with neonatal screening for GA1, some of
which are precisely the reverse of those quoted above:
(1) screening might be the only way to obtain a correct
estimation of the incidence; (2) screening would allow
for the implementation of prospective studies (e.g.
comparing the incidence of neurological disease in a
cohort of early-diagnosed patients with that occurring
‘‘naturally’’ in non-screened populations); (3) the addi-
tional costs would be limited, as GA1 would be part of a
‘‘package’’ of diseases detectable by TMS.
Screening comes of age
The time has come to abandon the concept of ‘‘perfect’’
screening, namely full sensitivity and complete treat-
ability, as an Allmachtsphantasie: we know this does
not hold true even for phenylketonuria or galactosa-
emia. We should depart from this all-or-none mentality
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and instead learn to measure the impact of our pre-
ventive and therapeutic measures using more objective
instruments such as burden of disease, quality of life
adjusted years and disability-adjusted quality of life-
years [19, 30]. This approach may also prove helpful in
increasing the economic resources allocated to neonatal
screening programmes [27].
Paediatricians involved in the care of children with
genetic disorders can rarely boast of a complete cure for
their patients, and learn instead to appreciate even small
advances in the quality of life. If we translate this to
GA1, being fully aware of the fact that we might not
help each and every patient, we should not miss the
chance of an early diagnosis – that is the best a baby
with GA1 can hope for.
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